Title :

Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study

Author(s) :

Javed, Sahir [Auteur]
Centre hospitalier [Valenciennes, Nord]
Benoist, Stéphane [Auteur]
AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
Devos, Patrick [Auteur]
Truant, Stéphanie [Auteur]
Guimbaud, Rosine [Auteur]
Institut Claudius Regaud
Lièvre, Astrid [Auteur]
Institut de Génétique et Développement de Rennes [IGDR]
CHU Pontchaillou [Rennes]
Sefrioui, David [Auteur]
Communications Cellulaires et Différenciation [CCD]
Cohen, Romain [Auteur]
Artru, Pascal [Auteur]
Hôpital privé Jean Mermoz [Lyon]
Dupré, Aurélien [Auteur]
Centre Léon Bérard [Lyon]
Bachet, Jean-Baptiste [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
de La Fouchardière, Christelle [Auteur]
Centre Léon Bérard [Lyon]
Ploquin, Anne [Auteur]
Turpin, Anthony [Auteur correspondant]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Journal title :

World Journal of Surgical Oncology

Pages :

131

Publisher :

BioMed Central

Publication date :

2022-04-23

ISSN :

1477-7819

English keyword(s) :

BRAF mutation
Colorectal cancer
Drug therapy
Liver metastasis surgery

HAL domain(s) :

Sciences du Vivant [q-bio]/Cancer

English abstract : [en]

BACKGROUND: BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains ...
Show more >BACKGROUND: BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains difficult due to the scarce literature. The aim was to study a large cohort of BRAF V600E-mutant CRLM patients in order to see if surgery extend overall survival among others prognostic factors. METHODS: BRAF V600E-mutant CRCs diagnosed with liver-only metastases, resected or not, were retrospectively identified between April 2008 and December 2017, in 25 French centers. Clinical, molecular, pathological characteristics and treatment features were collected. Overall survival (OS) was defined as the time from CRLM diagnosis to death from any cause. Cox proportional hazard models were used for statistical analysis. RESULTS: Among the 105 patients included, 79 (75%) received chemotherapy, 18 (17%) underwent upfront CRLM surgery, and 8 (8%) received exclusive best supportive care. CRLM surgery was performed in 49 (46.7%) patients. CRLM were mainly synchronous (90%) with bilobar presentation (61%). The median OS was 34 months (range, 28.9-67.3 months) for resected patients and 10.6 (6.7-12.5) months for unresected patients (P < 0.0001). In multivariate analysis, primary tumor surgery (hazard ratio (HR) = 0.349; 95% confidence interval (CI) 0.164-0.744, P = 0.0064) and CRLM resection (HR = 0.169; 95% CI 0.082-0.348, P < 0.0001) were associated with significantly better OS. CONCLUSIONS: In the era of systemic cytotoxic chemotherapies, liver surgery seems to extend OS in BRAF V600E-mutant CRCs with liver only metastases historical cohort.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL